Ivan Liachko

Seattle

Ivan Liachko previously served as Executive Officer, Director, and Promoter at Phase Genomics, Inc.

Phase Genomics Secures $2.5M to Develop AI Platform for Detecting Cancer Chromosomal Aberrations

Seattle startup Phase Genomics received $2.5 million in funding, including $2 million from the U.S. National Cancer Institute and $500,000 from Washington state's Andy Hill CARE Fund, to advance its AI-driven platform that detects chromosomal aberrations in cancer. The funding supports projects analyzing tumor samples to develop predictive scores for cancers like acute myeloid leukemia and colorectal cancer.

AI, startups, and Star Wars: Highlights from the GeekWire Awards

The theme at this week's GeekWire Awards was Star Wars, but we didn't need to go to a galaxy far, far away to find the force that promises to reshape the technology industry. The game-changing potential of AI was on the minds of many finalists and attendees, and integral to the business models of many of the companies featured on stage. This episode features conversations with finalists and attendees about the economy, artificial intelligence, and more ... plus lots of cool tech along the way. GeekWire Awards 2023 revealed: Community honors top innovation in Pacific Northwest tech Seattle Seahawks legend…

Grin Lord, CEO of Seattle’s mpathic, Finalist for Startup CEO of the Year at 2023 GeekWire Awards for Empathy-Driven Communication Software

Grin Lord, CEO and co-founder of Seattle startup mpathic, specializes in using empathy to improve corporate communication and is a finalist for Startup CEO of the Year at the 2023 GeekWire Awards. Her company applies machine learning to analyze conversations and foster empathy across industries such as insurance, healthcare, and human resources.

Phase Genomics CEO Ivan Liachko shifts company to R&D focus after pandemic hits revenue; one furlough, no layoffs

Phase Genomics, a five-year-old University of Washington spinoff led by CEO Ivan Liachko, shifted to skeleton lab crews and remote work during the pandemic, cutting revenue and furloughing one employee while focusing R&D inward to adapt and continue innovating. The company is adjusting its genomics technology amid Seattle's biotech disruption and exploring ways to help with COVID-19 research.

Organizations

  • Phase Genomics logo
    Phase Genomics Executive Officer, Director, Promoter 2017–present, CEO · current

Online